Haemonetics (NYSE:HAE) Announces Earnings Results, Beats Estimates By $0.04 EPS

Haemonetics (NYSE:HAE) posted its quarterly earnings data on Thursday. The medical instruments supplier reported $1.31 EPS for the quarter, topping the consensus estimate of $1.27 by $0.04, FiscalAI reports. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The business had revenue of $338.97 million for the quarter, compared to analyst estimates of $331.90 million. During the same quarter in the previous year, the firm posted $1.19 earnings per share. Haemonetics’s quarterly revenue was down 2.7% on a year-over-year basis. Haemonetics updated its FY 2026 guidance to 4.900-5.000 EPS.

Here are the key takeaways from Haemonetics’ conference call:

• Company raised full‑year guidance — reported revenue guidance tightened to a decline of ~1%–3%, organic revenue ex‑CSL raised to ~8%–10%, adjusted EPS now expected at $4.90–$5.00, and free cash flow guidance increased to $200–$220 million.
• Core product momentum — NexSys/TEG and Plasma drove outsized results (TEG adoption and a new heparinase cartridge accelerating conversions; Plasma organic growth ex‑CSL ~20% this quarter and ~22% YTD), with sustained share gains and innovation‑led pricing.
• Interventional Technologies (IVT) remains a drag — IVT revenue fell materially (down 12% Q/Q) due to esophageal cooling weakness, accelerated PFA adoption and OEM headwinds; management expects a turnaround in FY2027 but is investing now, so near‑term performance is challenged.
• Margins and cash generation strengthened — adjusted gross margin ~60%, operating‑margin guidance ~26%–27%, $74M free cash flow in the quarter (YTD $165M), cash balance up to $363M, active buybacks and the $61M Vivisure acquisition funded while keeping leverage manageable.

Haemonetics Price Performance

Shares of NYSE:HAE traded down $0.32 during mid-day trading on Thursday, reaching $65.63. The stock had a trading volume of 902,897 shares, compared to its average volume of 853,476. The business’s 50 day moving average price is $77.59 and its 200 day moving average price is $65.27. Haemonetics has a 1 year low of $47.31 and a 1 year high of $87.32. The company has a market cap of $3.07 billion, a P/E ratio of 19.15, a price-to-earnings-growth ratio of 1.35 and a beta of 0.28. The company has a current ratio of 1.64, a quick ratio of 1.03 and a debt-to-equity ratio of 1.08.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Haemonetics in a research note on Monday, December 29th. BTIG Research reaffirmed a “buy” rating and issued a $88.00 price target on shares of Haemonetics in a research report on Friday, January 9th. Robert W. Baird increased their price objective on shares of Haemonetics from $87.00 to $99.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. CJS Securities raised Haemonetics to a “strong-buy” rating in a research report on Thursday, December 11th. Finally, Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Haemonetics has an average rating of “Moderate Buy” and an average target price of $84.40.

Institutional Investors Weigh In On Haemonetics

Hedge funds have recently bought and sold shares of the business. Sivia Capital Partners LLC purchased a new stake in Haemonetics during the 2nd quarter valued at $234,000. Boothbay Fund Management LLC boosted its stake in Haemonetics by 75.4% during the third quarter. Boothbay Fund Management LLC now owns 5,002 shares of the medical instruments supplier’s stock worth $244,000 after buying an additional 2,150 shares during the period. Corient Private Wealth LLC increased its position in Haemonetics by 13.0% during the second quarter. Corient Private Wealth LLC now owns 5,233 shares of the medical instruments supplier’s stock valued at $390,000 after acquiring an additional 600 shares during the last quarter. Bayesian Capital Management LP purchased a new stake in shares of Haemonetics in the second quarter valued at $339,000. Finally, Quantinno Capital Management LP raised its stake in shares of Haemonetics by 9.0% in the second quarter. Quantinno Capital Management LP now owns 3,492 shares of the medical instruments supplier’s stock valued at $261,000 after acquiring an additional 289 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.